NASDAQ$MDRX
Veradigm Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Allscripts reported a consolidated revenue increase, driven by growth in Veradigm revenue and improved profitability, while also completing the sale of its Hospital and Large Physician Practices Segment.
Allscripts reported second quarter results with year-over-year growth in revenue, gross profit, and Adjusted EBITDA. The company completed the sale of its Hospital and Large Physician Practices Segment. Consolidated GAAP net loss totaled $64 million, while non-GAAP net income was $22 million.
- Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021
- Veradigm revenue was $145 million compared with $133 million in the second quarter of 2021
- Consolidated Allscripts revenue was $151 million compared with $141 million in the second quarter of 2021
- Generated $42 million of cash flow from continuing operations in the quarter
Headline financials
Revenue & EPS history
Allscripts · Revenue · Quarterly
$151M
Revenue by segment
Allscripts · $369M total across 2 segments · Q3 2021
- Software delivery, support...$223M—60.3%
- Client services$147M—39.7%
Forward guidance
Allscripts is affirming its prior annual outlook and currently expects to achieve:
Tailwinds
- Veradigm revenue growth year-over-year between 6% to 7%
- Veradigm Adjusted EBITDA growth year-over-year between 10% to 15%
- Free cash flow from continuing operations between $110 million to $120 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.3%
Avg return
Earnings day
-0.5%
Avg return
5 days after
-0.9%
Avg return
30 days after
38%
20 / 52 earnings
Positive
+21.1%
Q2 2020
Best reaction
-17.9%
Q3 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2022 | -0.2% | -0.8% | -1.3% | |
| Q3 2022 | +9.9% | +18.4% | +33.7% | |
| Q2 2022 | +11.1% | +9.6% | +5.4% | |
| Q1 2022 | +3.0% | +1.2% | -7.9% | |
| Q4 2021 | -2.1% | -0.2% | +9.4% | |
| Q3 2021 | +7.6% | +7.3% | +19.2% | |
| Q2 2021 | +1.7% | -0.3% | -11.1% | |
| Q1 2021 | +1.4% | +2.6% | +2.8% | |
| Q4 2020 | -4.8% | -6.4% | -5.6% | |
| Q2 2020 | +21.1% | +18.3% | +21.0% | |
| Q1 2020 | -7.2% | -14.8% | -10.1% | |
| Q4 2019 | -3.2% | +1.3% | -11.0% | |
| Q3 2019 | -4.1% | -3.5% | -13.5% | |
| Q2 2019 | -5.1% | -11.4% | -9.4% | |
| Q1 2019 | -0.3% | +1.4% | +3.5% | |
| Q4 2018 | -8.7% | -9.4% | -17.1% | |
| Q3 2018 | -17.9% | -10.7% | -15.2% | |
| Q2 2018 | -3.5% | -1.1% | +5.0% | |
| Q1 2018 | -2.3% | +0.0% | -5.9% | |
| Q4 2017 | +0.5% | +2.3% | -11.5% | |
| Q3 2017 | -3.5% | -2.2% | +10.5% | |
| Q2 2017 | +13.5% | +5.9% | +13.3% | |
| Q1 2017 | -1.4% | -2.1% | -5.5% | |
| Q4 2016 | +1.1% | -1.8% | -3.3% | |
| Q3 2016 | -9.8% | -11.5% | -9.6% | |
| Q2 2016 | -2.5% | -4.3% | -9.7% | |
| Q1 2016 | +3.5% | — | — | |
| Q4 2015 | +0.5% | — | — | |
| Q3 2015 | +4.5% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -1.3% | — | — | |
| Q4 2014 | +2.9% | — | — | |
| Q3 2014 | -16.8% | — | — | |
| Q2 2014 | -2.6% | — | — | |
| Q1 2014 | +1.6% | — | — | |
| Q4 2013 | +1.6% | — | — | |
| Q3 2013 | +1.5% | — | — | |
| Q2 2013 | -3.4% | — | — | |
| Q1 2013 | -0.9% | — | — | |
| Q4 2012 | -1.1% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +19.4% | — | — | |
| Q1 2012 | -0.0% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -2.8% | — | — | |
| Q2 2011 | -2.6% | — | — | |
| Q3 2010 | -0.2% | — | — | |
| Q2 2010 | -2.5% | — | — | |
| Q4 2009 | -2.5% | — | — | |
| Q1 2011 | +1.0% | — | — | |
| Q4 2010 | -3.4% | — | — | |
| Q1 2010 | -3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro